Alkem Labs completes acquisition of 100% stake in Adroit Biomed
Advertisement
Alkem Labs has completed the acquisition of a 100 percent stake in M/s. Adroit Biomed Limited in accordance with the conditions prescribed in the share purchase agreement dated 28th March, 2025.
Following the transaction, Adroit will now be a wholly owned subsidiary of the Company.
The acquisition is valued at Rs 140 crores, payable in two tranches, subject to adjustment on account of debt & debt like items & change in normalized working capital as on closing date and other appropriate closing adjustments, the company had earlier informed in its February BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.